Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Lancet Infectious Diseases
Oct 2019 Volume 19 Number 10 p1035-1148, e337-e369
http://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Sonya Abraham, et l